PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Atomoxetine hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs

PAD Profile : Atomoxetine hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs

Keywords :
Attention Deficit Hyperactivity Disorder
Brand Names Include :
Strattera, Atomaid

Traffic Light Status

Status 1 of 1.

Status :
Amber
Formulations :
  • Capsules
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Shared Care arrangements for children and adolescents with ADHD are in place with Surrey and Borders Partnership NHS Foundation Trust.

Guildford & Waverley, North West Surrey and Surrey Downs have agreed a Locally Commissioned Service (LCS) for practices entering into the shared care agreement with Surrey & Borders Partnership. The LCS supports the provision of an annual physical medication review by the GP (with an annual review by the specialist so that the patient continues to receive a 6-monthly review in accordance with the product license)
See below for a copy of the Shared care with LCS agreement

There is also a non-LCS shared care agreement that remains unchanged and is available for all non-LCS participating practices (see shared care agreement below)

Associated BNF Codes

04. Central Nervous System
04.04.00. CNS stimulants and drugs used for ADHD
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More